Xu Yang, Du Lihong, Soli Eric D, Braun Matthew P, Dean Dennis C, Musson Donald G
Merck Research Laboratories, Department of Drug Metabolism, WP75A-303, West Point, PA 19486, USA.
J Chromatogr B Analyt Technol Biomed Life Sci. 2005 Mar 25;817(2):287-96. doi: 10.1016/j.jchromb.2004.12.019.
To support pharmacokinetic studies, a selective and sensitive liquid chromatography/tandem mass spectrometry (LC-MS/MS) method has been developed and validated for the simultaneous determination of a novel KDR kinase inhibitor (1) and its active metabolite (2) in human plasma. The method is fully automated using a Packard MultiPROBE II system and a TomTec Quadra 96 liquid handling workstation to perform sample preparation and solid-phase extraction (SPE). Following the extraction on a mixed-mode SPE using Oasis MCX 96-well plate, the analytes were separated on a Aquasil C18 column (50 mm x 2.1 mm, i.d., 3 microm) with a mobile phase consisting of acetonitrile/ammonium acetate buffer (5 mM, pH 5.0) (60/40, v/v). The run time for each injection was 4.5 min with the retention times of approximately 2.0 and 2.7 min for 1 and 2 respectively, at a flow rate of 0.25 mL/min. A tandem mass spectrometric detection was conducted using multiple reaction monitoring (MRM) under the positive ion mode with a turbo ion-spray interface. The linear ranges of the calibration curves were 0.05-400 ng/mL for 1 and 0.1-400 ng/mL for 2 on a PE Sciex API 4000 LC-MS/MS system. The lower limits of quantitation (LLOQ) of the assay were 0.05 and 0.1 ng/mL for 1 and 2 respectively, when 0.4 mL of plasma was processed. Intra-day assay precision (using five standard curves prepared by spiking compounds to five lots of plasma) was less than 4.9% for 1 and less than 9.6% for 2 on each concentration. Assay accuracy was found to be 95.1-104.6% of nominal for 1 standards and 93.5-105.6% for 2 standards. QC samples were stable when kept at room temperature for 4 h, at -70 degrees C for 10 days, and after three freeze-thaw cycles. The extraction recoveries were 80%, 83% and 84% for 1 and 2 and I.S. respectively, and no significant matrix effects were observed. The method was successfully applied to plasma samples from clinical studies after oral administration of compound 1.
为支持药代动力学研究,已开发并验证了一种选择性和灵敏的液相色谱/串联质谱(LC-MS/MS)方法,用于同时测定人血浆中一种新型KDR激酶抑制剂(1)及其活性代谢物(2)。该方法使用Packard MultiPROBE II系统和TomTec Quadra 96液体处理工作站进行样品制备和固相萃取(SPE),实现了完全自动化。在使用Oasis MCX 96孔板进行混合模式SPE萃取后,分析物在Aquasil C18柱(50 mm×2.1 mm,内径,3μm)上分离,流动相由乙腈/醋酸铵缓冲液(5 mM,pH 5.0)(60/40,v/v)组成。每次进样的运行时间为4.5分钟,化合物1和2的保留时间分别约为2.0分钟和2.7分钟,流速为0.25 mL/min。使用涡轮离子喷雾接口在正离子模式下通过多反应监测(MRM)进行串联质谱检测。在PE Sciex API 4000 LC-MS/MS系统上,校准曲线的线性范围对于化合物1为0.05 - 400 ng/mL,对于化合物2为0.1 - 400 ng/mL。当处理0.4 mL血浆时,该测定方法的定量下限(LLOQ)对于化合物1和2分别为0.05和0.1 ng/mL。日内测定精密度(使用将化合物加入五批血浆中制备的五条标准曲线)在每个浓度下,化合物1小于4.9%,化合物2小于9.6%。测定准确度对于化合物1标准品为标称值的95.1 - 104.6%,对于化合物2标准品为93.5 - 105.6%。质量控制样品在室温下保存4小时、在 - 70℃下保存10天以及经过三次冻融循环后均稳定。化合物1、2和内标物的萃取回收率分别为80%、83%和84%,未观察到明显的基质效应。该方法成功应用于口服化合物1后临床研究的血浆样品。